Enzalutamide + Abiraterone + Placebo for Enzalutamide + Prednisone
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
Oct 22, 2013 → Aug 31, 2022
NCT ID
NCT01995513About Enzalutamide + Abiraterone + Placebo for Enzalutamide + Prednisone
Enzalutamide + Abiraterone + Placebo for Enzalutamide + Prednisone is a approved stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01995513. Target conditions include Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01995513 | Approved | Completed |
Competing Products
20 competing products in Prostate Cancer